期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Tissue Inhibitor of Metalloprotease-1(TIMP-1)Regulates Adipogenesis of Adipose-derived Stem Cells(ASCs)via the Wnt Signaling Pathway in an MMP-independent Manner 被引量:3
1
作者 Lu WANG Chen-guang ZHANG +1 位作者 Yu-lin JIA Li HU 《Current Medical Science》 SCIE CAS 2020年第5期989-996,共8页
Tissue inhibitor of m etalloprotease-1(TIM P-1)is a tissue inhibitor o f matrix metalloproteinases(MMPs).It however exerts multiple effects on biological processes,such as cell growth,proliferation,differentiation and... Tissue inhibitor of m etalloprotease-1(TIM P-1)is a tissue inhibitor o f matrix metalloproteinases(MMPs).It however exerts multiple effects on biological processes,such as cell growth,proliferation,differentiation and apoptosis,in an MMP-independent manner.This study aimed to examine the role of TIMP-1 in adipogenesis of adipose-derived stem cells(ASCs)and the underlying mechanism.We knocked down the TIMP-1 gene in ASCs through lentiviral vectors encoding TIMP-1 small interfering RNA(siRNA),and then found that the knockdown of TIMP-1 in ASCs promoted the adipogenic differentiation of stem cells and inhibited the Wnt/β-catenin signaling pathway in ASCs.We also noted that mutant TIMP-1 without the inhibitory activity on MMPs promoted the activation of Wnt/β-catenin pathway as well as the recombinant wild type TIMP-1 did,which indicated that the effect of TIMP-1 on Wnt/β-catenin pathway was MMPindependent.Our study suggested that TIMP-1 negatively regulated the adipogenesis of ASCs via the Wnt/β-catenin signaling pathway in an MMP-independent manner. 展开更多
关键词 tissue inhibitor of metalloproteinase 1 adipose-derived stem cells ADIPOGENESIS wnt/P-catenin pathway
下载PDF
血清DKK1、Survivin水平与难治性多发性骨髓瘤患者FVAD方案化疗疗效的关系 被引量:4
2
作者 赵建强 倪增峰 +1 位作者 贾文华 马李洁 《中国煤炭工业医学杂志》 2021年第5期526-529,共4页
目的探讨血清Wnt通路抑制抑制因子Dickkopf-1(DKK1)、凋亡抑制蛋白生存素(Survivin)与难治性多发性骨髓患者FVAD方案(氟达拉滨、长春新碱、表阿霉素和地塞米松)化疗疗效的关系。方法选取2017年1月—2019年1月在西安医学院第一附属医院... 目的探讨血清Wnt通路抑制抑制因子Dickkopf-1(DKK1)、凋亡抑制蛋白生存素(Survivin)与难治性多发性骨髓患者FVAD方案(氟达拉滨、长春新碱、表阿霉素和地塞米松)化疗疗效的关系。方法选取2017年1月—2019年1月在西安医学院第一附属医院治疗的难治性多发性骨髓瘤患者81例,均给予FVAD方案化疗,观察治疗效果,检测血清DKK1、Survivin水平。结果达到完全缓解(CR)患者23例,部分缓解(PR)患者31例,疾病稳定(SD)患者17例,疾病进展(PD)患者10例,治疗有效率为66.67%;治疗有效患者治疗后血清KK1、Survivin水平分别为(3.54±0.97)ng/ml和(81.46±5.57)ng/L,明显低于治疗无效患者,差异有统计学意义(P<0.05);治疗前后血清DKK1、Survivin水平变化值预测患者治疗有效的ROC曲线下面积分别为0.733和0.693,差异有统计学意义(P<0.05),截断值分别为4.03ng/ml和26.54ng/L,灵敏性分别为77.80%和88.00%,特异性分别为63.00%和48.10%。结论在难治性多发性骨髓瘤患者中,FVAD方案化疗有效者治疗后DKK1、Survivin水平明显降低,治疗前后变化值在预测治疗疗效中有一定应用价值。 展开更多
关键词 wnt通路抑制抑制因子dickkopf-1 凋亡抑制蛋白生存素 难治性多发性骨髓瘤 FVAD方案
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部